Table. Pregnant people with laboratory-confirmed parvovirus B19 infection and complications, Denmark, January 2014–April 2024 (n = 565).
| Characteristics | Interepidemic 2014–2023a | Epidemic 2017 | Epidemic 2024 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | % | Incidenceb | n | % | Incidenceb | n | % | Incidenceb | |
| Pregnant people | 379 | 5.4 | 56 | 22.8 | 130 | 56.1 | |||
| Pregnant people with severe adverse outcome | 38 | 10 | 63.4 | 5 | 8.9 | 24.4 | 16 | 12.3 | 82.8 |
| Type of severe outcomec | |||||||||
| Anaemia | 11 | 2.9 | 1.8 | 2 | 3.6 | 9.8 | 8 | 6.2 | 41.4 |
| Fetal hydrops | 4 | 1.1 | 0.7 | 1 | 1.8 | 4.9 | 1 | 0.8 | 5.2 |
| Miscarriage | 26 | 6.9 | 4.4 | 2 | 3.6 | 9.8 | 5 | 3.8 | 25.9 |
| Fetal transfusion | 2 | 0.5 | 0.3 | 3 | 5.4 | 14.7 | 9 | 6.9 | 46.6 |
a The epidemic months in 2017 (March–June) are not included.
b Incidence is calculated as an average per month for the epidemic periods, which in 2017 was March–June and in 2024 January–April 2024.
c Individuals may have experienced multiple outcomes and two pregnant individuals had foetal transfusions without a diagnosis of either anaemia, hydrops fetalis or miscarriage in the national inpatient registry.